{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:31:16Z","timestamp":1789446676216,"version":"build-2803163510"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T00:00:00Z","timestamp":1491955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of personalized medicine is to offer a tailored approach to each patient in order to provide the most effective therapy, while reducing risks and side effects. The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated major benefits in heart failure with reduced ejection fraction (HFrEF), results with challenging inconsistencies in heart failure with preserved ejection fraction (HFpEF), and \u2018neutral\u2019 preliminary results in acute heart failure. Data derived from landmark trials are generally applied in a \u2018one size fits all\u2019 manner and the development and implementation of more personalized MRA management would offer the potential to improve outcomes and reduce side effects. However, the personalization of pharmacotherapy regimens remains poorly defined in the cardiovascular field (in light of current knowledge) and until further trials targeting specific subpopulations have been conducted, MRAs should be provided to the great majority of HFrEF patients in the absence of contraindication. Spironolactone should be considered for symptomatic HFpEF patients with elevated natriuretic peptides. In the near future, trials should target HFrEF patients using exclusion criteria sourced from landmark trials (e.g. severe renal impairment), select more homogeneous HFpEF populations (e.g. with elevated BNP and structural abnormalities on echocardiography), and determine which patients are likely to benefit from MRAs (e.g. according to prespecified biomarkers).<\/jats:p>","DOI":"10.1002\/ejhf.814","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T01:06:38Z","timestamp":1491959198000},"page":"974-986","source":"Crossref","is-referenced-by-count":30,"title":["Tailoring Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Patients: Are We Moving Towards a Personalized Approach?"],"prefix":"10.1093","volume":"19","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Centre d'Investigation Clinique Plurith\u00e9matique 1433, INSERM U1116, University of Lorraine , Nancy ,","place":["France"]},{"name":"Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute and Division of Cardiology, Department of Medicine, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pizard","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique Plurith\u00e9matique 1433, INSERM U1116, University of Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique Plurith\u00e9matique 1433, INSERM U1116, University of Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,12]]},"reference":[{"key":"2026011721192766100_ejhf814-bib-0001","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1093\/eurheartj\/ehu312","article-title":"The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology","volume":"35","author":"Kirchhof","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"2026011721192766100_ejhf814-bib-0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2047487312448991","article-title":"Risk-guided therapy: a first step to personalized medicine","volume":"19","author":"Zannad","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0003","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0735-1097(01)01761-2","article-title":"A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission","volume":"39","author":"Kasper","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ACI.0b013e3283609831","article-title":"Post-hoc data analysis: benefits and limitations","volume":"13","author":"Curran-Everett","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2026011721192766100_ejhf814-bib-0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"key":"2026011721192766100_ejhf814-bib-0006","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.diabet.2015.06.004","article-title":"Review of heart failure treatment in type 2 diabetes patients: it's at least as effective as in non-diabetic patients!","volume":"41","author":"Girerd","year":"2015","journal-title":"Diabetes Metab"},{"key":"2026011721192766100_ejhf814-bib-0007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2015.07.023","article-title":"A systematic assessment of absolute treatment effect","volume":"116","author":"Ferreira","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2015.08.008","article-title":"To the Editor \u2013 Diabetes and sudden death: let's assess the absolute risk increase rather than the proportional risk from sudden cardiac death!","volume":"12","author":"Coiro","year":"2015","journal-title":"Heart Rhythm"},{"key":"2026011721192766100_ejhf814-bib-0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721192766100_ejhf814-bib-0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721192766100_ejhf814-bib-0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026011721192766100_ejhf814-bib-0012","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0013","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0014","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","article-title":"Race influences the safety and efficacy of spironolactone in severe heart failure","volume":"6","author":"Vardeny","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0015","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jacc.2006.07.030","article-title":"Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial","volume":"48","author":"McNamara","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.amjcard.2007.02.097","article-title":"Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure","volume":"100","author":"Biolo","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.2015101152","article-title":"Genome-wide association of CKD progression: the Chronic Renal Insufficiency Cohort Study","volume":"28","author":"Parsa","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026011721192766100_ejhf814-bib-0018","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Rales Investigators. Circulation"},{"key":"2026011721192766100_ejhf814-bib-0019","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10741-005-2351-3","article-title":"Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure","volume":"10","author":"Zannad","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2026011721192766100_ejhf814-bib-0020","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.11904","article-title":"Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"314","author":"Cooper","year":"2015","journal-title":"JAMA"},{"key":"2026011721192766100_ejhf814-bib-0021","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/pst.531","article-title":"Subgroup analyses of clinical effectiveness to support health technology assessments","volume":"10","author":"Paget","year":"2011","journal-title":"Pharm Stat"},{"key":"2026011721192766100_ejhf814-bib-0022","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0023","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/eht247","article-title":"The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial","volume":"34","author":"Collier","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721192766100_ejhf814-bib-0024","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0026","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ejhf.303","article-title":"Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)","volume":"17","author":"Cannon","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0027","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ejhf.485","article-title":"Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study","volume":"18","author":"Chin","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0028","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/bph.13479","article-title":"Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats","volume":"173","author":"Youcef","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2026011721192766100_ejhf814-bib-0029","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0030","first-page":"195","article-title":"Obesity and the obesity paradox in heart failure","volume":"31","author":"Gupta","year":"2015","journal-title":"Can J Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2008.02.014","article-title":"Body mass index and mortality in heart failure: a meta-analysis","volume":"156","author":"Oreopoulos","year":"2008","journal-title":"Am Heart J"},{"key":"2026011721192766100_ejhf814-bib-0032","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0033","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011721192766100_ejhf814-bib-0035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721192766100_ejhf814-bib-0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026011721192766100_ejhf814-bib-0037","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.114.013637","article-title":"Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west","volume":"131","author":"Rossignol","year":"2015","journal-title":"Circulation"},{"key":"2026011721192766100_ejhf814-bib-0038","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ejhf.326","article-title":"Geographic differences in heart failure trials","volume":"17","author":"Ferreira","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0039","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/eurheartj\/eht071","article-title":"International differences in treatment effect: do they really exist and why?","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721192766100_ejhf814-bib-0040","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.jacc.2015.10.023","article-title":"Statistical controversies in reporting of clinical trials: Part 2 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0041","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacbts.2016.03.001","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2026011721192766100_ejhf814-bib-0042","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0043","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0044","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026011721192766100_ejhf814-bib-0045","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0046","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026011721192766100_ejhf814-bib-0047","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-014-0261-8","article-title":"Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"2026011721192766100_ejhf814-bib-0048","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026011721192766100_ejhf814-bib-0049","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.acvd.2014.01.010","article-title":"Heart failure with systolic dysfunction complicating acute myocardial infarction \u2013 differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: a post hoc substudy of the EPHESUS trial","volume":"107","author":"Carillo","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"2026011721192766100_ejhf814-bib-0050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/eurjhf\/hfp136","article-title":"Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial","volume":"11","author":"Adamopoulos","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0051","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/eurheartj\/ehv273","article-title":"Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial","volume":"36","author":"Girerd","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721192766100_ejhf814-bib-0052","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejim.2013.08.711","article-title":"Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure","volume":"25","author":"Ferreira","year":"2014","journal-title":"Eur J Intern Med"},{"key":"2026011721192766100_ejhf814-bib-0053","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00392-013-0588-8","article-title":"Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors","volume":"102","author":"Ferreira","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0054","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00392-015-0945-x","article-title":"Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect","volume":"105","author":"Ferreira","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"2026011721192766100_ejhf814-bib-0055","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jchf.2016.06.003","article-title":"Rationale and design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure","volume":"4","author":"Butler","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0056","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"2026011721192766100_ejhf814-bib-0057","first-page":"417","article-title":"Single-dose i.v. aldactone for congestive heart failure: a preliminary observation","volume":"21","author":"Ceremuzynski","year":"1983","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"2026011721192766100_ejhf814-bib-0058","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"2026011721192766100_ejhf814-bib-0059","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0060","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721192766100_ejhf814-bib-0061","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2026011721192766100_ejhf814-bib-0062","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"2026011721192766100_ejhf814-bib-0063","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.athoracsur.2012.05.023","article-title":"The impact of complete revascularization on long-term survival is strongly dependent on age","volume":"94","author":"Girerd","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"2026011721192766100_ejhf814-bib-0064","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jclinepi.2013.08.010","article-title":"Number needed to treat from absolute risk and incidence rate: how to make apples and oranges comparable?","volume":"67","author":"Girerd","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2026011721192766100_ejhf814-bib-0065","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"2026011721192766100_ejhf814-bib-0066","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2026011721192766100_ejhf814-bib-0067","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7555\/JBR.28.20140045","article-title":"Heart \u2018omics\u2019 in AGEing (HOMAGE): design, research objectives and characteristics of the common database","volume":"28","author":"Jacobs","year":"2014","journal-title":"J Biomed Res"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/8\/974\/66328448\/eurjhf_19_8_974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/8\/974\/66328448\/eurjhf_19_8_974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:21:33Z","timestamp":1768702893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/8\/974\/8418575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,12]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,4,12]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.814","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,4,12]]}}}